When should Neratini, often mentioned by breast cancer friends, be considered for use?

01 Nairatini: The “mixed trick” to reduce the recurrence of breast cancer, we know that Her-2-positive breast cancer has the characteristics of reoccurrence, hair and transferability, although the current treatments, such as single or double-target tulip resistance, have significantly increased the patient’s lifetime (1, but this does not mean that he/she can sleep well). Previous studies have shown[2] that patients are actively receiving post-operative assistive treatment for tratochorus (1 year) combination of chemotherapy, with 31 per cent of relapses occurring after 10 years. At this point, Nairatini’s gleaming as the “best defense” can effectively reduce the risk of re-emergence of breast cancer. – A clinical study called ExteNET showed [3,4] that Nairatini was treated for one year after a single anti-treatment with a significant reduction of 33 per cent (P=0.0091) and 27 per cent (P=0.0083) in five years. That’s why the doctors recommended the continuation of Neiratini intensive care, which would protect cancer cells from re-emergence, but would all breast cancer patients be suitable for Niratini? How can I be judged to be unfit for Nairadini? As mentioned earlier, Nairadini can reduce relapse, so patients with a higher risk of relapse are better suited to use Naratini, including the following two groups: 1) Her-2-positive early breast cancer patients have completed surgery and are at medium-risk re-emergence risk (2 cm tumours < 3 cm maximum radium or no regional lympho transfer beyond this range, as long as the combined regional lymphosis transfer is a high-risk patient) [1] Her-2-positive breast cancer patients have completed surgery and have not fully reduced their pathology after new assistive treatment before surgery [1] (means non-invasive disease in the breast and abreath) so when is the best time for these patients to activate Naratini? According to the results of the ExteNET study [4], if Nairatini treatment is initiated within one year (including one year) of the tratophorus monotherapy treatment, iDFS* benefits more than those patients who began treatment after one year, so the earlier the Nilatini effect is better. For Naratini treatment time, the guidelines recommend a year-long Nalatini intensive treatment [1]. *iDFS refers to the non-invasive rate of survival, which is used to describe the absence of tumour recurrences in breast cancer patients for some time after treatment. The term “invasive” here refers to the ability of cancer cells to attack the surrounding tissue or to spread to other parts of the body through the blood and lymphocyte system, in contrast to early cancers, which are confined to their original hair. So do you understand now? After a year of trato-chorus anti-treatment, Nairatini should begin to be eaten as soon as possible, as soon as possible, as soon as possible, and as soon as possible as possible as possible, of course, the specific treatment will have to follow the medical instructions! Reference: 1. China Cancer Control Association Breast Cancer Specialist Committee, China Medical Association's Oncology Section, Breast Oncology Group, Shun Chi-min. Chinese Society against Cancer Breast Cancer Guidelines and Guidelines for Breast Cancer Care and Treatment (2024 edition) [J]. China Cancer Journal, 2023,33 (12): 1092-1186.2. Cameron D, et al. Lancet 2017; 389 (10075): 1195-1205. Chan, et al. Lancet Oncol 2016; 17 (3): 367-377.4. Martin M, et al. Lancet Oncol 2017; 18 (1288): 1688-1700.